BD Expands VIASURE Assays for the BD MAX™ System
BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent global leader in medical technology, is thrilled to enhance its diagnostic offerings with the inclusion of new IVDR-certified VIASURE assays. This strategic expansion is set to improve respiratory and sexually transmitted infection (STI) diagnostics in Europe, following rigorous certification processes for the new assays developed in collaboration with Certest Biotec.
Introduction of New assay in the BD MAX™ Portfolio
The newly certified assays are designed to provide rapid and accurate detection of various pathogens. This expansion represents a significant advancement for clinical laboratories aiming to deliver timely diagnostics. The new additions to the BD MAX™ System portfolio include:
VIASURE Respiratory Virus Extended Mix Assay
The VIASURE Respiratory Virus Extended Mix Real-Time PCR Detection Kit is a state-of-the-art tool that enables the detection of multiple respiratory viruses. This includes pathogens such as SARS-CoV-2, influenza A/B, respiratory syncytial virus (RSV), parainfluenza virus, human coronaviruses, and more, all from a single nasopharyngeal swab. This kind of efficiency in testing is crucial for managing respiratory virus outbreaks.
VIASURE HSV-1, HSV-2 & Treponema pallidum Assay
The VIASURE HSV-1, HSV-2 & Treponema pallidum Assay is another innovative addition. This assay effectively identifies herpes simplex viruses and the bacteria responsible for syphilis from samples taken via anogenital and oral skin lesion swabs. Such precise identification is critical for the diagnosis and treatment of STIs, leading to improved patient outcomes.
Commitment to Innovation in Diagnostics
Philippe Villiard, Vice President of BD Diagnostic Solutions in Europe, stated, "With these two assays, we are adding clinically relevant, targeted molecular panels to our already broad respiratory and STI menu. Our partnership with Certest Biotec has been instrumental in expanding the BD MAX™ System menu and supports our commitment to delivering innovative diagnostic solutions that enable faster, more comprehensive detection of infectious diseases on the BD MAX™ System." This collaboration highlights BD's dedication to enhancing diagnostic efficiency and effectiveness across medical facilities.
Capabilities of the BD MAX™ System
The BD MAX™ System is revolutionizing how labs manage diagnostics. With the capability to process up to 24 samples per run, it accommodates a wide range of assays covering healthcare-associated infections (HAIs), respiratory illnesses, gastrointestinal pathogens, STIs, and women’s health needs. This system integrates real-time PCR technology with automated nucleic acid extraction and amplification in a streamlined workflow. Moreover, results are available in approximately three hours, requiring less than one minute of hands-on time per sample. This efficiency assists clinicians in making timely and informed treatment decisions, ultimately enhancing patient care.
Looking Towards the Future with Certest Biotec
Certest's CEO, Nelson Fernandes, expressed excitement about the continued partnership with BD. He noted, "Our collaboration, which began in 2017, continues to grow. We are confident that our joint efforts will result in exceptional projects in the future." This ongoing relationship underscores the commitment of both organizations to advancing diagnostic capabilities.
About BD
BD is one of the largest and most innovative medical technology companies globally. The company is focused on advancing healthcare through improved medical discovery, diagnostics, and care delivery. BD partners with healthcare providers to develop groundbreaking technologies, services, and solutions that optimize clinical therapies and processes. Their workforce of over 70,000 employees is dedicated to enhancing both safety and efficiency in healthcare settings, striving to ensure that all patients receive top-tier care.
About Certest Biotec
Certest Biotec, founded in 2002, specializes in the development and commercialization of in vitro diagnostic medical devices. Operating on a global scale, the company is divided into four primary business areas that include raw materials, immunodiagnostics, molecular biology, and pharma. Certest prides itself on delivering high-quality, reliable solutions to medical diagnostic professionals through its advanced laboratory capabilities and skilled workforce.
Frequently Asked Questions
1. What are the new assays introduced by BD?
The new assays include the VIASURE Respiratory Virus Extended Mix assay and the VIASURE HSV-1, HSV-2 & Treponema pallidum assay.
2. How does the BD MAX™ System assist clinical laboratories?
It allows laboratories to process up to 24 samples at once with results available in about three hours, streamlining the workflow.
3. What is the significance of these new assays?
They enhance the ability to detect a wide range of pathogens quickly and accurately, improving treatment and patient outcomes.
4. How long has BD partnered with Certest Biotec?
BD has been collaborating with Certest Biotec since 2017, focusing on advancing diagnostic technologies.
5. What is the ultimate goal of BD's innovations?
The goal is to advance healthcare by improving diagnostic accuracy, efficiency, and overall patient care.
